Literature DB >> 22966381

A rare case of Philadelphia chromosome-positive chronic myelogenous leukemia with inversion in chromosome 9 and t(10;17).

Walid Al Achkar1, Abdulsamad Wafa, Hasmik Mkrtchyan, Faten Moassass, Thomas Liehr.   

Abstract

The reciprocal translocation t(9;22)(q34;q11), leading to the formation of two fusion genes, BCR/ABL and ABL/BCR, is found in 90-95% of cases with chronic myeloid leukemia (CML). ABL-BCR expression does not correlate with prognosis, as assessed by cytogenetic response, since the ABL/BCR gene is expressed in only a proportion of CML patients. This study examined an exceptional BCR/ABL-positive CML case with inversion in 9q22q34 leading to the absence of ABL/BCR. Moreover, an unbalanced translocation between chromosomes 10 and 17 which caused deletion of the TP53 gene was identified. The TP53 gene plays a potential role in CML progression, and loss of TP53 may be regarded as a poor prognostic factor.

Entities:  

Year:  2010        PMID: 22966381      PMCID: PMC3436397          DOI: 10.3892/ol_00000138

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  13 in total

1.  Microdissection based high resolution multicolor banding for all 24 human chromosomes.

Authors:  Thomas Liehr; Anita Heller; Heike Starke; Nikolai Rubtsov; Vladimir Trifonov; Kristin Mrasek; Anja Weise; Alma Kuechler; Uwe Claussen
Journal:  Int J Mol Med       Date:  2002-04       Impact factor: 4.101

2.  Demystifying chromosome preparation and the implications for the concept of chromosome condensation during mitosis.

Authors:  U Claussen; S Michel; P Mühlig; M Westermann; U-W Grummt; K Kromeyer-Hauschild; T Liehr
Journal:  Cytogenet Genome Res       Date:  2002       Impact factor: 1.636

Review 3.  The biology of CML blast crisis.

Authors:  Bruno Calabretta; Danilo Perrotti
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

4.  Molecular definition of high-resolution multicolor banding probes: first within the human DNA sequence anchored FISH banding probe set.

Authors:  Anja Weise; Kristin Mrasek; Ina Fickelscher; Uwe Claussen; Sau Wai Cheung; Wei Wen Cai; Thomas Liehr; Nadezda Kosyakova
Journal:  J Histochem Cytochem       Date:  2008-02-05       Impact factor: 2.479

5.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

Authors:  T G Lugo; A M Pendergast; A J Muller; O N Witte
Journal:  Science       Date:  1990-03-02       Impact factor: 47.728

Review 6.  p53 in hematologic malignancies.

Authors:  J Imamura; I Miyoshi; H P Koeffler
Journal:  Blood       Date:  1994-10-15       Impact factor: 22.113

7.  Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia.

Authors:  Alistair G Reid; Brian J P Huntly; Colin Grace; Anthony R Green; Elisabeth P Nacheva
Journal:  Br J Haematol       Date:  2003-05       Impact factor: 6.998

8.  Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.

Authors:  Alfonso Quintas-Cardama; Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Mary Beth Rios; Kimberly Hayes; Armand Glassman; B Nebiyou Bekele; Xian Zhou; Jorge Cortes
Journal:  Blood       Date:  2004-11-30       Impact factor: 22.113

9.  Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia.

Authors:  J V Melo; A Hochhaus; X H Yan; J M Goldman
Journal:  Br J Haematol       Date:  1996-03       Impact factor: 6.998

Review 10.  Chronic myeloid leukemia in 2007.

Authors:  Jolynn Sessions
Journal:  Am J Health Syst Pharm       Date:  2007-12-15       Impact factor: 2.637

View more
  1 in total

Review 1.  The structural basis for cancer treatment decisions.

Authors:  Ruth Nussinov; Hyunbum Jang; Chung-Jung Tsai
Journal:  Oncotarget       Date:  2014-09-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.